💊 Obat A-Z 🧬 Target 🛠 Alat 📚 Panduan
Semua Obat Kelas Obat Area Terapeutik Efek Samping
Panduan Glosarium Linimasa
Perbandingan Perjalanan Obat Famili Obat
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Carfilzomib

CHEMBL451887 Phase 4 Disetujui Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
719.9 g/mol
LogP
4.7
Phase
4

A proteasome inhibitor that selectively and irreversibly blocks the activity of the proteasome, disrupting protein degradation pathways that cancer cells depend on for survival. It is used intravenously to treat relapsed or refractory multiple myeloma. Cardiovascular monitoring is important during treatment due to the risk of cardiac complications.

Berat Molekul

719,9000 g/mol

LogP

4,70

TPSA

158,00 Ų

Lipinski RO5

Lulus

Area Terapeutik

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Lymphoma Hypertension Breast Cancer Heart Failure Prostate Cancer Colorectal Cancer Leukemia

Mekanisme Kerja

Inhibits the 26S proteasome, blocking the ubiquitin-proteasome pathway of intracellular protein degradation. This leads to accumulation of pro-apoptotic proteins and induces cell death in rapidly dividing cancer cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Inhibits the 26S proteasome, blocking the ubiquitin-proteasome pathway of intracellular protein degradation. This leads to accumulation of pro-apoptotic proteins and induces cell death in rapidly dividing cancer cells.

Struktur 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1

                

                

                
                

                    
InChI

                    
InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C40H57N5O7

                    

                    
                    

                        
HBD / HBA

                        
4 / 8

                    

                    
                    

                        
Ikatan yang Dapat Dirotasi

                        
20

                    

                    
                    
                    

                        
Atom Berat

                        
52

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Pertanyaan yang Sering Diajukan

                

                    
                    

                        
                        

                            
A proteasome inhibitor that selectively and irreversibly blocks the activity of the proteasome, disrupting protein degradation pathways that cancer cells depend on for survival. It is used intravenously to treat relapsed or refractory multiple myeloma. Cardiovascular monitoring is important during treatment due to the risk of cardiac complications.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits the 26S proteasome, blocking the ubiquitin-proteasome pathway of intracellular protein degradation. This leads to accumulation of pro-apoptotic proteins and induces cell death in rapidly dividing cancer cells.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Carfilzomib is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL451887.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 11556711.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Penyangkalan Medis

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.